**Abstract ATU-9**

**AMBULATORY CARE MANAGEMENT OF 70 PATIENTS WITH ACUTE SEVERE UC IN COMPARISON TO 700 INPATIENTS**

1Kamal Patel*, 2Jonathan Segal, 3Shaji Sebastian, 4Alexandra Kent, 5Lucy Hicks, 6Shameer Mehta, 7Matthew Brookes, 8Chris Lamb, 9Nicholas Kennedy, 10Garerth Walker. 1St George’s University Hospitals Nhs Foundation Trust, London, UK; 2Imperial College London, London, UK; 3Hull University Teaching Hospitals NHS Trust, Hull, UK; 4King’s College Hospital NHS Foundation Trust, London, UK; 5University College London Hospitals NHS Foundation Trust, London, UK; 6Royal Wolverhampton NHS Trust, Wolverhampton, UK; 7Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK; 8Royal Devon and Exeter NHS Foundation Trust, Exeter, UK; 9Torbay and South Devon NHS Foundation Trust, Torbay, UK.

10.1136/gutjnl-2021-BSG.42

**Introduction** Acute severe ulcerative colitis (ASUC) traditionally requires inpatient hospital management for intravenous therapies and/or colectomy. Patients with ASUC can deteriorate rapidly and hence require close monitoring of vital signs correlated with clinical, biochemical and radiological investigations. Traditionally, patients are admitted to hospital to facilitate endoscopic assessment, exclude concomitant infective complications, monitor response to first-line corticosteroid treatment and determine the need for and timing of rescue therapy and/or colectomy. Ambulatory care pathways, which utilise outpatient monitoring and drug delivery, have been shown to deliver safe and effective treatment for conditions which have historically mandated hospitalisation e.g. pulmonary embolus. To date there are a paucity of data regarding the use of ambulatory pathways in ASUC cohorts. We used data from PROTECT, a UK multicentre observational COVID-19 inflammatory bowel disease (IBD) study, to report the extent, safety and effectiveness of ASUC ambulatory pathways.

**Methods** Adults (≥18 years old) meeting Truelove and Witts criteria between 01/01/2019- 01/06/2019 and 01/03/2020-30/06/2020 were recruited to PROTECT (Abstract ATU9 Figure 1). We utilised demographic, disease phenotype, treatment outcomes and 3-month follow-up data. Primary outcome was rate of rescue therapy and/or colectomy. Secondary outcomes included corticosteroid response, response to rescue therapy, colectomy, mortality and hospital readmission within 3-months. We compared outcomes in 3 cohorts: i) patients treated entirely in **inpatient** setting; ambulatory patients subdivided into ii) patients hospitalised and **subsequently discharged to ambulatory care**; iii) patients managed as **ambulatory from diagnosis**.

**Results** 38%(23/60) participating hospitals used ambulatory pathways. Of 770 eligible patients, 700(91%) patients received entirely inpatient care, 55(7%) patients were discharged to ambulatory pathways and 15(2%) patients were managed as ambulatory from diagnosis. The rate of rescue therapy and/or colectomy (49%(339/696) vs 41%(22/54) vs 67%(10/15), respectively, p=0.18) (Abstract ATU9 figure 2) and secondary outcomes were similar among all three cohorts. After 3-months follow up from the index ASUC diagnosis there was no significant difference in either rate of UC flare, readmission to hospital with UC flare or colectomy between the cohorts.

**Conclusions** In the largest description of ambulatory ASUC care to date, we report an emerging practice which challenges treatment paradigms. We recommend that patients managed in the ambulatory setting are reviewed by gastroenterologists on a daily basis to monitor clinical parameters and assess for potential complications including venous thromboembolism and biochemical disturbance. Our data suggest ambulatory ASUC treatment may be safe and effective in selected patients but further studies exploring clinical and cost effectiveness as well as patient and physician acceptability are needed.

![Abstract ATU-9 Figure 1](link-to-image)

![Abstract ATU-9 Figure 2](link-to-image)